Directed evolution towards protease-resistant hirudin variants

Molecular Genetics and Metabolism

Volumn 80, Issue 4, 2003, Pages 451-462

  Wirsching, Frank ^a   Keller, Martina ^a   Hildmann, Christian ^a   Riester, Daniel ^a   Schwienhorst, Andreas ^a  

^a Inst fuer Mikrobiologie und Genetik   (Germany)

Author keywords

Directed evolution; Hirudin; Phage display; Protease resistance; Thrombin inhibitor design

Indexed keywords

ASPARTIC ACID; CHYMOTRYPSIN; HISTIDINE; PEPSIN A; POLYPEPTIDE; PROLINE; PROTEINASE; RECOMBINANT HIRUDIN; THROMBIN; THROMBIN INHIBITOR;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONFORMATION; CRYSTAL STRUCTURE; DRUG IDENTIFICATION; DRUG SCREENING; ELECTRICITY; HYDROPHOBICITY; IC 50; MOLECULAR EVOLUTION; MUTATION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; WILD TYPE;

EID: 0344493788     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymgme.2003.09.007     Document Type: Article

References (39)

1. Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe-Seyler's Z. Physiol. Chem. 308:1957;147-156.
2. Bode W., Huber R. Ligand binding: proteinase-protein inhibitor interactions. Curr. Opin. Struct. Biol. 1:1991;45-52.
3. Braun P.J., Dennis S., Hofsteenge J., Stone S.R. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry. 27:1988;6517-6522.
4. Chang J.-Y. Production, properties, and thrombin inhibitory mechanism of hirudin amino-terminal core fragments. J. Biol. Chem. 265:1990;22159-22166.
5. Degryse E., Acker M., Defreyn G., Bernat A., Maffrand J.P., Roitsch C., Courtney M. Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin. Protein Eng. 2:1989;459-465.
6. Dodt J., Köhler S., Baici A. Interaction of site specific hirudin variants with α-thrombin. FEBS Lett. 229:1988;87-90.
7. Maraganore J.M., Bourdon P., Jablonski K.L., Ramachandran K.L., FentonII J.W. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 29:1990;7095-7101.
8. Wallace A., Dennis S., Hofsteenge J., Stone S.R. Contribution of the N-terminal region of hirudin to its interaction with thrombin. Biochemistry. 28:1989;10079-10084.
9. Wirsching F., Luge C., Schwienhorst A. Modular design of a novel chimeric protein with combined thrombin inhibitory activity and plasminogen activating potential. Mol. Genet. Metab. 75:2002;250-259.
10. Vindigni A., De Filippis V., Zanotti G., Visco C., Orsini G., Fontana A. Probing the structure of hirudin from Hirudinaria manillensis by limited proteolysis. Isolation, characterization and thrombin-inhibitory properties of N-terminal fragments. Eur. J. Biochem. 226:1994;323-333.
11. Rydel T.J., Ravichandran K.G., Tulinsky A., Bode W., Huber R., Roitsch C., Fenton J.W. The structure of a complex of recombinant hirudin and human α-thrombin. Science. 249:1990;277-280.
12. Grütter M.G., Priestle J.P., Rahuel J., Grossenbacher H., Bode W., Hofsteenge J., Stone S.R. Crystal structure of the thrombin-hirudin complex: novel mode of serine protease inhibition. EMBO J. 9:1990;2361-2365.
13. Bichler J., Fichtl B., Siebeck M., Fritz H. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Arzeinm Forsch./Drug Res. 38:1988;704-710.
14. Fishman W.H., Doellgast G.J. Putnam F.W. The Plasma Proteins, Structure, Function and Genetic Control. vol. 2:1975;213-261 Academic Press, London.
15. Tsuda Y., Cygler M., Gibbs B.F., Pedyczak A., Féthière J., Yue S.Y., Konishi Y. Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors. Biochemistry. 33:1994;14443-14451.
16. Bichler J., Baynes J.W., Thorpe S.R. Catabolism of hirudin and thrombin-hirudin complexes in the rat. Biochem. J. 296:1993;771-776.
17. Zinchenko A.A., Rumsh L.D., Antonov V.K. Bioorg. Chem. (USSR). 2:1976;803.
18. Kasper C.B. Needleman S.B. Protein Sequence Determination. 1975;114-161 Springer-Verlag, New York.
19. Poschel K.A., Bucha E., Esslinger H.U., Nortersheuser P., Jansa U., Schindler S., Nowak G., Stein G. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure. Kidney Int. 58:2000;2478-2484
20. Bossavy J.P., Sakariassen K.S., Rubsamen K., Thalamas C., Boneu B., Cadroy Y. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 19:1999;1348-1353.
21. Esslinger H.U., Haas S., Maurer R., Lassmann A., Dubbers K., Muller-Peltzer H. Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers. Thromb. Haemost. 77:1997;911-919.
22. Tomandl D., Schober A., Schwienhorst A. Optimizing doped libaries by using genetic algorithms. J. Comput. Aided Mol. Des. 11:1997;29-38.
23. Wirsching F., Opitz T., Dietrich R., Schwienhorst A. Display of functional thrombin inhibitor hirudin on the surface of phage M13. Gene. 204:1997;177-184.
24. Szewczuk Z., Gibbs B.F., Yue S.Y., Purisima E.O., Konishi Y. Conformationally restricted thrombin inhibitors resistant to proteolytic digestion. Biochemistry. 31:1992;9132-9140.
25. Rydel T.J., Tulinsky A., Bode W., Huber R. Refined structure of the hirudin-thrombin complex. JMB. 221:1991;583-601.
26. Betz A., Hofsteenge J., Stone S.R. Interaction of the N-terminal region of hirudin with the active-site cleft of thrombin. Biochemistry. 31:1992;4557-4562.
27. Scharf M., Engels J., Tripier D. Primary structures of new 'iso-hirudins'. FEBS Lett. 255:1989;105-110.
28. R. Maschler, V. Steiner, M.G. Grütter, R. Fritz, DNA vector and recombinant host cell for production of hirullin P6 and P18, Eur. Patent Application 89810414.6, EP-AP0347376, 1988.
29. Krstenansky J.L., Mao S.J.T. Structure-function relationships of the C-terminal functional domain of hirudin and its variants. Blood Coagul. Fibrinolysis. 2:1991;91-96.
30. Lazar J.B., Winant R.C., Johnson P.H. Hirudin: amino-terminal residues play a major role in the interaction with thrombin. J. Biol. Chem. 266:1991;685-688.
31. De Filippis V., Colombo G., Russo I., Spadari B., Fontana A. Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 41:2002;13556-13569.
32. Robinson M., Lilley R., Little S., Emtage J.S., Yarranton G., Stephens P., Millican A., Eaton M., Humphreys G. Codon usage can affect efficiency of translation of genes in Escherichia coli. NAR. 12:1984;6663-6671.
33. Bonekamp F., Jensen K.F. The AGG codon is translated slowly in E. coli even at very low expression levels. NAR. 16:1988;3013-3024.
34. Brinkmann U., Mattes R.E., Buckel P. High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product. Gene. 85:1989;109-114.
35. 45-65 FEBS Lett. 211:1987;10-16.
36. Maraganore J.M., Chao B., Joseph M.L., Jablonski J., Ramachandran K.L. Anticoagulant activity of synthetic hirudin peptides. J. Biol. Chem. 264:1989;8692-8698.
37. Ni F., Konishi Y., Scheraga H.A. Thrombin-bound conformation of the C-terminal fragmens of hirudin determined by transferred nuclear overhauser effects. Biochemistry. 29:1990;4479-4489.
38. LeBonniec B.F., Betz A., Guinto E.R., Esmon C.T., Stone S.R. Mapping of the thrombin des-ETW conformation by using site-directed mutants of hirudin. Evidence for the induction of nonlocal modifications by mutagenesis. Biochemistry. 33:1994;3959-3966.
39. Fischer G., Bang H., Berger E., Schellenberger A. Conformational specificity of chymotrypsin toward proline-containing substrates. Biochim. Biophys. Acta. 79:1984;87-97.